Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SPIRIVA
- Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure
- Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler
- Phase 4 COPD and Suboptimal Inspiratory Flow Rate
- Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)
- Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler®
- Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
- Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler
- PIFR-based Inhalation Therapy in Patients Recovering From AECOPD
- A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)
- Optical Coherence Tomography for Assessment of the Treatment Effect of Tiotropium in Early Stage of COPD
- Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (CO
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COP
- Pharmacokinetic Study Comparing Tiotropium Easyhaler and Spiriva Handihaler
- Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment
- Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma
- Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Reference
- Two-period 21 Day Cross-over Study to Compare the Pharmacokinetics of Tiotropium From Two Inhalers
- Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product
- Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness
- Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium
- Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
- Description of the Ability to Learn How to Handle Inhaler Devices in COPD
- Cross-over Study in Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Test and Reference Products
- Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge
- Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD
- Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis
- Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD
- Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
- Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)
- Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary
- Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011)
- 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo
- Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients
- A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD
- A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects
- Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects
- Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers
- Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease
- A Prescription-Event Monitoring (PEM) Study of Tiotropium
- Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy
- Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.
- Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation
- Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice
- Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD
- Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)
- Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
- To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
- Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
- Beta Blocker Therapy in Moderate to Severe COPD
- Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test
- Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Ri
- Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD
- Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China
- Closing Volume Interpretation and Bronchodilators Effect
- Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study
- Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)
- Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography
- Effects of Tiotropium on Walking Capacity in Patients With COPD
- Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)
- Tiotropium Bromide in Cystic Fibrosis
- Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
- The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease
- Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD
- Bronchodilators and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease (COPD) Patients
- The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations
- Tiotropium/Salmeterol Inhalation Powder in COPD
- Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD
- Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol PE Capsule) in COPD
- Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice
- Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines
- RUSSE / Russian Spiriva® Safety & Efficacy Study
- Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation
- Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema
- Dynamic Hyperinflation and Tiotropium
- Tiotropium for Smoking Asthmatics Study
- Tiotropium In Exercise
- Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.
- Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
- A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)
- Spiriva® Assessment of FEV1 (SAFE)
- Tiotropium (Spiriva) Rehabilitation Study
- Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients
- SPIRIVA in Ususal Care
- Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva
- Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD
- Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)
- Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory Disorders
- A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)
- Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)
- Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD
- A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
- Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).
- Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients
- Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
- A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (C
- 12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)
Clinical trials list
click for details